Stay updated on Pralsetinib vs Standard of Care in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T23:18:33.000Z thumbnail image
  5. Check
    30 days ago
    No Change Detected
  6. Check
    38 days ago
    Change Detected
    Summary
    The webpage has added several new healthcare locations in Italy, including specific hospitals and their addresses, while removing some previously listed locations and dates. Additionally, there is a notice regarding heavy traffic affecting NLM-NCBI services.
    Difference
    7%
    Check dated 2025-02-10T16:47:31.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T11:50:56.000Z thumbnail image
  8. Check
    59 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-20T03:23:28.000Z thumbnail image
  9. Check
    66 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    0.2%
    Check dated 2025-01-12T23:17:59.000Z thumbnail image
  10. Check
    74 days ago
    Change Detected
    Summary
    The study has added 68 new locations across various countries, including Brazil, Spain, and Costa Rica, while removing 88 locations, primarily in the United States and Europe, indicating a significant shift in the geographical focus of the research.
    Difference
    22%
    Check dated 2025-01-05T16:14:06.000Z thumbnail image

Stay in the know with updates to Pralsetinib vs Standard of Care in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.